Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) major shareholder Paul B. Manning acquired 1,333,333 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was bought at an average price of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the acquisition, the insider now directly owns 1,333,333 shares in the company, valued at approximately $2,999,999.25. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Taysha Gene Therapies Stock Performance
Shares of TSHA stock traded up $0.04 during trading hours on Monday, reaching $2.28. The company had a trading volume of 365,366 shares, compared to its average volume of 2,750,745. The business has a fifty day moving average price of $2.97 and a 200-day moving average price of $2.42. Taysha Gene Therapies, Inc. has a one year low of $0.61 and a one year high of $4.32. The firm has a market cap of $426.41 million, a PE ratio of -4.57 and a beta of 0.42. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.38 and a current ratio of 3.38.
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The firm had revenue of $3.41 million during the quarter, compared to analyst estimates of $3.70 million. During the same period in the previous year, the business posted ($0.28) earnings per share. Sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.43 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on TSHA
Institutional Trading of Taysha Gene Therapies
Several large investors have recently added to or reduced their stakes in TSHA. Schonfeld Strategic Advisors LLC bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $2,275,000. Adage Capital Partners GP L.L.C. bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $4,740,000. Acuta Capital Partners LLC bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $12,096,000. Kynam Capital Management LP bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $10,369,000. Finally, RTW Investments LP bought a new stake in Taysha Gene Therapies during the third quarter valued at approximately $53,382,000. 77.70% of the stock is currently owned by institutional investors.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
See Also
- Five stocks we like better than Taysha Gene Therapies
- Are Penny Stocks a Good Fit for Your Portfolio?
- Applied Digital Boosts Stock with Cutting-Edge AI Data Centers
- How to Capture the Benefits of Dividend Increases
- Chewy Stock Surges on Roaring Kitty’s Disclosure of Major Stake
- Election Stocks: How Elections Affect the Stock Market
- How to Invest in Gold: A Complete Guide
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.